GB0317466D0 - Use - Google Patents

Use

Info

Publication number
GB0317466D0
GB0317466D0 GBGB0317466.1A GB0317466A GB0317466D0 GB 0317466 D0 GB0317466 D0 GB 0317466D0 GB 0317466 A GB0317466 A GB 0317466A GB 0317466 D0 GB0317466 D0 GB 0317466D0
Authority
GB
United Kingdom
Prior art keywords
mediates
inhibits
medicament
gene
enzyme
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0317466.1A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Sheffield
Original Assignee
University of Sheffield
Newcastle University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27772701&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB0317466(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of Sheffield, Newcastle University filed Critical University of Sheffield
Priority to GBGB0317466.1A priority Critical patent/GB0317466D0/en
Publication of GB0317466D0 publication Critical patent/GB0317466D0/en
Priority to CN201210332472.8A priority patent/CN102935230B/zh
Priority to DK04743564.9T priority patent/DK1649017T4/da
Priority to PT04743564T priority patent/PT1649017E/pt
Priority to NZ545307A priority patent/NZ545307A/en
Priority to CA2533332A priority patent/CA2533332C/en
Priority to PL04743516T priority patent/PL1660095T3/pl
Priority to AT04743516T priority patent/ATE454893T1/de
Priority to RU2006105652/04A priority patent/RU2404183C2/ru
Priority to SI200431370T priority patent/SI1660095T1/sl
Priority to PT04743516T priority patent/PT1660095E/pt
Priority to PCT/GB2004/003183 priority patent/WO2005012305A2/en
Priority to HK06106961.6A priority patent/HK1084602B/en
Priority to DE602004025123T priority patent/DE602004025123D1/de
Priority to NZ544989A priority patent/NZ544989A/en
Priority to CN2004800273183A priority patent/CN1856313B/zh
Priority to HK07100334.8A priority patent/HK1094006B/xx
Priority to AT04743564T priority patent/ATE516353T1/de
Priority to AU2004261462A priority patent/AU2004261462B2/en
Priority to EP04743516A priority patent/EP1660095B1/en
Priority to KR1020067001725A priority patent/KR101138471B1/ko
Priority to DK04743516.9T priority patent/DK1660095T3/da
Priority to AU2004261779A priority patent/AU2004261779B2/en
Priority to JP2006520907A priority patent/JP5519097B2/ja
Priority to KR1020067001650A priority patent/KR101136702B1/ko
Priority to US10/565,308 priority patent/US7531530B2/en
Priority to EP04743564.9A priority patent/EP1649017B2/en
Priority to MXPA06000993A priority patent/MXPA06000993A/es
Priority to GB0603874A priority patent/GB2419882B/en
Priority to PCT/GB2004/003235 priority patent/WO2005012524A1/en
Priority to BRPI0412899-0A priority patent/BRPI0412899B1/pt
Priority to US10/555,507 priority patent/US8859562B2/en
Priority to ES04743516T priority patent/ES2339663T3/es
Priority to BRPI0412909-1A priority patent/BRPI0412909B1/pt
Priority to US10/898,653 priority patent/US7351701B2/en
Priority to CN2004800272941A priority patent/CN1856572B/zh
Priority to JP2006521648A priority patent/JP5466814B2/ja
Priority to PL04743564T priority patent/PL1649017T5/pl
Priority to CA2533423A priority patent/CA2533423C/en
Priority to ES04743564.9T priority patent/ES2367433T5/es
Priority to IL173336A priority patent/IL173336A/en
Priority to ZA2006/00679A priority patent/ZA200600679B/en
Priority to ZA200601386A priority patent/ZA200601386B/en
Priority to NO20060906A priority patent/NO338398B1/no
Priority to NO20060928A priority patent/NO334610B1/no
Priority to CY20101100309T priority patent/CY1110335T1/el
Priority to JP2011246988A priority patent/JP5547164B2/ja
Priority to JP2011260401A priority patent/JP5580280B2/ja
Priority to JP2013147532A priority patent/JP5848728B2/ja
Priority to HK13109407.3A priority patent/HK1182016B/xx
Priority to US14/322,759 priority patent/US20150005327A1/en
Priority to US15/650,459 priority patent/US20180000822A1/en
Priority to US16/598,808 priority patent/US20200237762A1/en
Priority to US17/528,034 priority patent/US20220062286A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/02—Pentosyltransferases (2.4.2)
    • C12Y204/0203—NAD+ ADP-ribosyltransferase (2.4.2.30), i.e. tankyrase or poly(ADP-ribose) polymerase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Lubricants (AREA)
GBGB0317466.1A 2003-07-25 2003-07-25 Use Ceased GB0317466D0 (en)

Priority Applications (54)

Application Number Priority Date Filing Date Title
GBGB0317466.1A GB0317466D0 (en) 2003-07-25 2003-07-25 Use
CN201210332472.8A CN102935230B (zh) 2003-07-25 2004-07-23 抑制PARP活性的RNAi用于生产治疗癌症的药物的用途
DK04743564.9T DK1649017T4 (da) 2003-07-25 2004-07-23 Anvendelse af RNA i inhiberende PARP aktivitet til fremstillingen af et lægemiddel til behandlingen af cancer
PT04743564T PT1649017E (pt) 2003-07-25 2004-07-23 Utilização de arni inibidor da actividade de parp para o fabrico de um medicamento para tratamento do cancro
NZ545307A NZ545307A (en) 2003-07-25 2004-07-23 Use of RNAI inhibiting parp activity for the manufacture of a medicament for the treatment of cancer
CA2533332A CA2533332C (en) 2003-07-25 2004-07-23 Therapeutic compounds
PL04743516T PL1660095T3 (pl) 2003-07-25 2004-07-23 Tricykliczne inhibitory PARP
AT04743516T ATE454893T1 (de) 2003-07-25 2004-07-23 Tricyclische parp-hemmer
RU2006105652/04A RU2404183C2 (ru) 2003-07-25 2004-07-23 Трициклические ингибиторы парп
SI200431370T SI1660095T1 (sl) 2003-07-25 2004-07-23 Triciklični parp inhibitorji
PT04743516T PT1660095E (pt) 2003-07-25 2004-07-23 Inibidores tricíclicos de parp
PCT/GB2004/003183 WO2005012305A2 (en) 2003-07-25 2004-07-23 Tricyclic parp inhibitors
HK06106961.6A HK1084602B (en) 2003-07-25 2004-07-23 Tricyclic parp inhibitors
DE602004025123T DE602004025123D1 (en) 2003-07-25 2004-07-23 Tricyclische parp-hemmer
NZ544989A NZ544989A (en) 2003-07-25 2004-07-23 Tricyclic PARP inhibitors
CN2004800273183A CN1856313B (zh) 2003-07-25 2004-07-23 治疗化合物
HK07100334.8A HK1094006B (en) 2003-07-25 2004-07-23 Use of rnai inhibiting parp activtiy for the manufacture of a medicament for the treatment of cancer
AT04743564T ATE516353T1 (de) 2003-07-25 2004-07-23 Verwendung von rnai mit inhibierender parp aktivität zur herstelllung eines arzneimittels zur behandlung von krebs
AU2004261462A AU2004261462B2 (en) 2003-07-25 2004-07-23 Tricyclic PARP inhibitors
EP04743516A EP1660095B1 (en) 2003-07-25 2004-07-23 Tricyclic parp inhibitors
KR1020067001725A KR101138471B1 (ko) 2003-07-25 2004-07-23 트리시클로 ｐａｒｐ 저해제
DK04743516.9T DK1660095T3 (da) 2003-07-25 2004-07-23 Tricykliske PARP-inhibitorer
AU2004261779A AU2004261779B2 (en) 2003-07-25 2004-07-23 Use of RNAi inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer
JP2006520907A JP5519097B2 (ja) 2003-07-25 2004-07-23 癌を治療するための医薬の製造におけるＰＡＲＰ活性阻害性ＲＮＡｉの使用
KR1020067001650A KR101136702B1 (ko) 2003-07-25 2004-07-23 암 치료용 약제를 제조하기 위한 ｐａｒｐ 활성을 억제하는ｒｎａｉ의 용도
US10/565,308 US7531530B2 (en) 2003-07-25 2004-07-23 Therapeutic compounds
EP04743564.9A EP1649017B2 (en) 2003-07-25 2004-07-23 Use of rnai inhibiting parp activity for the manufacture of a medicament for the treatment of cancer
MXPA06000993A MXPA06000993A (es) 2003-07-25 2004-07-23 Inhbidores triciclicos de parp.
GB0603874A GB2419882B (en) 2003-07-25 2004-07-23 Use of rnai inhibiting parp activity for the manufacture of a medicament for the treatment of cancer
PCT/GB2004/003235 WO2005012524A1 (en) 2003-07-25 2004-07-23 Use of rnai inhibiting parp activtiy for the manufacture of a medicament for the treatment of cancer
BRPI0412899-0A BRPI0412899B1 (pt) 2003-07-25 2004-07-23 Uso de um composto ou um sal farmaceuticamente aceitável do mesmo para a manufatura de um medicamento citotóxico para o tratamento de câncer de ovário, câncer de mama, câncer de próstata ou câncer pancreático
US10/555,507 US8859562B2 (en) 2003-07-25 2004-07-23 Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer
ES04743516T ES2339663T3 (es) 2003-07-25 2004-07-23 Inhibidores de parp triciclicos.
BRPI0412909-1A BRPI0412909B1 (pt) 2003-07-25 2004-07-23 Uso de um inibidor de poli (adp-ribose) polimerase 1 (parp-1) para a fabricação de um medicamento para o tratamento de células de câncer defeituosas em recombinação homóloga
US10/898,653 US7351701B2 (en) 2003-07-25 2004-07-23 Therapeutic compounds
CN2004800272941A CN1856572B (zh) 2003-07-25 2004-07-23 抑制PARP活性的RNAi用于生产治疗癌症的药物的用途
JP2006521648A JP5466814B2 (ja) 2003-07-25 2004-07-23 治療用化合物
PL04743564T PL1649017T5 (pl) 2003-07-25 2004-07-23 Zastosowanie aktywności PARP hamującej RNAI do wytwarzania leku do leczenia raka
CA2533423A CA2533423C (en) 2003-07-25 2004-07-23 Use of rnai inhibiting parp activity for the manufacture of a medicament for the treatment of cancer
ES04743564.9T ES2367433T5 (es) 2003-07-25 2004-07-23 Uso de la actividad PARP inhibidora de ARNI para la fabricación de un medicamento para el tratamiento del cáncer
IL173336A IL173336A (en) 2003-07-25 2006-01-24 Derivatives of epsilon-lactam fused with indole and benzimidazole for the treatment of cancer caused by a genetic defect in the gene
ZA2006/00679A ZA200600679B (en) 2003-07-25 2006-01-24 Therapeutic compounds
ZA200601386A ZA200601386B (en) 2003-07-25 2006-02-16 Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer
NO20060906A NO338398B1 (no) 2003-07-25 2006-02-24 Anvendelse av en poly(ADP-ribose) polymerase (PARP)-inhibitor for fremstilling av et medikament for behandling av cancerceller som er defekte med hensyn på homolog rekombinasjon (HR) og en poly(ADP-ribose) polymerase (PARP)-inhibitor for anvendelse ved behandling av cancerceller som er defekte med hensyn på homolog rekombinasjon (HR).
NO20060928A NO334610B1 (no) 2003-07-25 2006-02-24 Terapeutiske forbindelser og anvendelse av en terapeutisk effektiv mengde av forbindelsene for fremstilling av et cytotoksisk medikament for behandling av kreft, hvor kreften er forårsaket av en genetisk defekt i et gen som medierer homolog rekombinasjon
CY20101100309T CY1110335T1 (el) 2003-07-25 2010-03-31 Τρικυκλικοι αναστολεις parp
JP2011246988A JP5547164B2 (ja) 2003-07-25 2011-11-11 癌を治療するための医薬の製造におけるＰＡＲＰ活性阻害性ＲＮＡｉの使用
JP2011260401A JP5580280B2 (ja) 2003-07-25 2011-11-29 治療用化合物
JP2013147532A JP5848728B2 (ja) 2003-07-25 2013-07-16 癌を治療するための医薬の製造におけるＰＡＲＰ活性阻害性ＲＮＡｉの使用
HK13109407.3A HK1182016B (en) 2003-07-25 2013-08-12 Use of rnai inhibiting parp activtiy for the manufacture of a medicament for the treatment of cancer
US14/322,759 US20150005327A1 (en) 2003-07-25 2014-07-02 Use of RNAI Inhibiting PARP Activity for the Manufacture of a Medicament for the Treatment of Cancer
US15/650,459 US20180000822A1 (en) 2003-07-25 2017-07-14 Use of RNAI Inhibiting PARP Activity for the Manufacture of a Medicament for the Treatment of Cancer
US16/598,808 US20200237762A1 (en) 2003-07-25 2019-10-10 Use of rnai inhibiting parp activity for the manufacture of a medicament for the treatment of cancer
US17/528,034 US20220062286A1 (en) 2003-07-25 2021-11-16 Use of rnai inhibiting parp activity for the manufacture of a medicament for the treatment of cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0317466.1A GB0317466D0 (en) 2003-07-25 2003-07-25 Use

Publications (1)

Publication Number Publication Date
GB0317466D0 true GB0317466D0 (en) 2003-08-27

Family

ID=27772701

Family Applications (2)

Application Number Title Priority Date Filing Date
GBGB0317466.1A Ceased GB0317466D0 (en) 2003-07-25 2003-07-25 Use
GB0603874A Expired - Lifetime GB2419882B (en) 2003-07-25 2004-07-23 Use of rnai inhibiting parp activity for the manufacture of a medicament for the treatment of cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
GB0603874A Expired - Lifetime GB2419882B (en) 2003-07-25 2004-07-23 Use of rnai inhibiting parp activity for the manufacture of a medicament for the treatment of cancer

Country Status (18)

Country Link
US (5) US8859562B2 (enExample)
EP (1) EP1649017B2 (enExample)
JP (3) JP5519097B2 (enExample)
KR (1) KR101136702B1 (enExample)
CN (3) CN1856572B (enExample)
AT (1) ATE516353T1 (enExample)
AU (1) AU2004261779B2 (enExample)
BR (1) BRPI0412909B1 (enExample)
CA (1) CA2533423C (enExample)
DK (1) DK1649017T4 (enExample)
ES (1) ES2367433T5 (enExample)
GB (2) GB0317466D0 (enExample)
NO (1) NO338398B1 (enExample)
NZ (1) NZ545307A (enExample)
PL (1) PL1649017T5 (enExample)
PT (1) PT1649017E (enExample)
WO (1) WO2005012524A1 (enExample)
ZA (1) ZA200601386B (enExample)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6956035B2 (en) 2001-08-31 2005-10-18 Inotek Pharmaceuticals Corporation Isoquinoline derivatives and methods of use thereof
CN100398519C (zh) 2003-02-28 2008-07-02 伊诺泰克制药公司 四环苯甲酰胺衍生物及其用法
GB0317466D0 (en) * 2003-07-25 2003-08-27 Univ Sheffield Use
MXPA06000993A (es) 2003-07-25 2006-08-31 Cancer Rec Tech Ltd Inhbidores triciclicos de parp.
SG150548A1 (en) * 2003-12-01 2009-03-30 Kudos Pharm Ltd Dna damage repair inhibitors for treatment of cancer
WO2006078503A2 (en) * 2005-01-07 2006-07-27 Arqule, Inc. Compositions for modulation of parp and methods for screening for same
CA2595290C (en) 2005-01-19 2013-06-25 Mgi Gp, Inc. Diazabenzo[de]anthracen-3-one compounds and methods for inhibiting parp
RU2007135362A (ru) 2005-02-25 2009-03-27 Инотек Фармасьютикалз Корпорейшн (Us) Тетрациклические амино- и карбоксамидосоединения и способ их применения
CN101316592A (zh) 2005-08-24 2008-12-03 伊诺泰克制药公司 茚并异喹啉酮类似物及其用法
JP2009517403A (ja) * 2005-11-25 2009-04-30 ユニバーシティー オブ メディシン アンド デンティストリー オブ ニュージャージー Ｐａｒｐ−１阻害剤の使用
JP2010506939A (ja) 2006-10-20 2010-03-04 ダナ ファーバー キャンサー インスティテュート，インコーポレイテッド ガンを処置するためのｄｎａ損傷修復阻害剤および方法
PT2099442E (pt) * 2006-12-26 2015-02-10 Pharmacyclics Inc Métodos de utilização de inibidores de histona desacetilase e monitorização de biomarcadores em terapia de combinação
MX2009009183A (es) 2007-02-28 2009-09-07 Inotek Pharmaceuticals Corp Analogos de indenoisoquinolinona y metodos de utilizacion de los mismos.
GB0707556D0 (en) * 2007-04-19 2007-05-30 Isis Innovation Treatment for cancer
JP5335673B2 (ja) 2007-06-20 2013-11-06 学校法人 埼玉医科大学 子宮癌、乳癌、及び膀胱癌の予防乃至治療に好適な二本鎖核酸分子、癌細胞増殖抑制剤、並びに医薬
WO2009027650A1 (en) * 2007-08-24 2009-03-05 The Institute Of Cancer: Royal Cancer Hospital Materials and methods for exploiting synthetic lethality in brca-associated cancers
SI2209375T1 (sl) 2007-10-03 2014-12-31 Eisai Inc. Spojine inhibitorja PARP in metode uporabe
WO2009113579A1 (ja) 2008-03-11 2009-09-17 学校法人埼玉医科大学 癌の予防乃至治療に好適な二本鎖核酸分子、癌細胞増殖抑制剤、並びに医薬
JP2012507010A (ja) * 2008-10-24 2012-03-22 マグナケム インターナショナル ラボラトリーズ， インコーポレイテッド Ｒａｄ９と選択的に相互作用する化合物をスクリーニングするための方法
US8268550B2 (en) * 2009-06-26 2012-09-18 Massachusetts Institute Of Technology Compositions and methods for identification of PARP function, inhibitors, and activators
WO2010151664A2 (en) 2009-06-26 2010-12-29 Massachusetts Institute Of Technology Compositions and methods for treating cancer and modulating stress granule formation
US8435961B2 (en) * 2009-06-26 2013-05-07 Massachusetts Institute Of Technology Methods and compositions for increasing the activity of inhibitory RNA
WO2011058367A2 (en) 2009-11-13 2011-05-19 Astrazeneca Ab Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor
ES2704303T3 (es) 2010-08-24 2019-03-15 Dana Farber Cancer Inst Inc Procedimientos para la predicción de una respuesta contra el cáncer
SG189280A1 (en) * 2010-10-07 2013-05-31 Agency Science Tech & Res Parp-1 inhibitors
MX368261B (es) 2011-07-22 2019-09-25 Pacylex Pharmaceuticals Inc Letalidad sintetica y el tratamiento de cancer.
ES2687024T3 (es) * 2012-02-23 2018-10-23 Children's Medical Center Corporation Procedimientos para predecir la respuesta contra el cáncer
US9359367B2 (en) 2012-07-09 2016-06-07 Lupin Limited Tetrahydroquinazolinone derivatives as PARP inhibitors
EP2986709A4 (en) * 2013-04-16 2017-03-15 University Of Washington Through Its Center For Commercialization Activating an alternative pathway for homology-directed repair to stimulate targeted gene correction and genome engineering
AU2014321200A1 (en) * 2013-09-23 2016-05-05 The University Of Chicago Methods and compositions relating to cancer therapy with DNA damaging agents
EP3102680B1 (en) 2014-02-07 2018-12-19 VIB vzw Inhibition of neat1 for treatment of solid tumors
US9889141B2 (en) * 2014-10-14 2018-02-13 Institute For Cancer Research Combined inhibition of the vitamin D receptor and poly(ADP) ribose polymerase (PARP) in the treatment of cancer
PL3277321T3 (pl) 2015-04-01 2024-11-18 Anaptysbio, Inc. Przeciwciała skierowane przeciwko białku 3 immunoglobuliny limfocytów t i mucyny (tim-3)
EP3325662B1 (en) 2015-07-17 2023-08-30 Pacylex Pharmaceuticals Inc. Epigenetic silencing of nmt2
KR20180059922A (ko) 2015-10-02 2018-06-05 유니버시티 오브 코펜하겐 히스톤 리더 도메인을 차단하는 소분자
DK3653709T3 (da) 2016-02-22 2021-03-08 Caribou Biosciences Inc Fremgangsmåder til modulering af dna-reparationsresultater
MA50677A (fr) * 2016-11-01 2021-07-14 Anaptysbio Inc Anticorps dirigés contre la protéine d'immunoglobuline de lymphocytes t et mucine 3 (tim-3)
AU2018205401B2 (en) 2017-01-09 2025-01-02 Tesaro, Inc. Methods of treating cancer with anti-TIM-3 antibodies
CN107058233A (zh) * 2017-05-03 2017-08-18 上海长海医院 一种减小肿瘤细胞对抗肿瘤药物的耐药性的方法
CN108048465A (zh) * 2017-12-20 2018-05-18 李风玲 一种抑制PARP基因用于治疗乳腺癌的siRNA
US10519136B2 (en) 2017-12-29 2019-12-31 Accutar Biotechnology Dual inhibitors of PARP1 and CDK
AU2019205325A1 (en) 2018-01-05 2020-08-13 Cybrexa 1, Inc. Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
KR20210097124A (ko) 2018-10-30 2021-08-06 리페어 세라퓨틱스 인크. 화합물, 약제 조성물, 및 화합물 제조 방법 및 atr 키나제 억제제로서의 이것들의 사용 방법
PH12021552205A1 (en) * 2019-03-25 2022-06-13 Cyteir Therapeutics Inc Combinations of rad51 and parp inhibitors
BR112022000297A2 (pt) 2019-07-10 2022-03-15 Cybrexa 3 Inc Conjugados de peptídeos de agentes de alvo de microtúbulos como terapêuticos
MX2022000449A (es) 2019-07-10 2022-04-25 Cybrexa 2 Inc Conjugados peptídicos de citotoxinas como terapéuticos.
KR20220035925A (ko) 2019-07-22 2022-03-22 리페어 세라퓨틱스 인크. Atr 키나제 억제제로서의 치환된 2-모르폴리노피리딘 유도체
CN116234803B (zh) 2019-12-23 2026-06-30 冰洲石生物科技公司 用于治疗癌症的雌激素受体降解剂和细胞周期蛋白依赖性激酶抑制剂的组合
ES3014370T3 (en) 2020-04-28 2025-04-22 Rhizen Pharmaceuticals Ag Novel compounds useful as poly(adp-ribose) polymerase (parp) inhibitors
WO2022090938A1 (en) 2020-10-31 2022-05-05 Rhizen Pharmaceuticals Ag Phthalazinone derivatives useful as parp inhibitors
CN114836472A (zh) * 2021-02-01 2022-08-02 中国人民解放军军事科学院军事医学研究院 PARP-1shRNA重组慢病毒载体、该载体稳定转染HaCaT的细胞系及其应用
WO2022215034A1 (en) 2021-04-08 2022-10-13 Rhizen Pharmaceuticals Ag Inhibitors of poly(adp-ribose) polymerase
AU2022276986B2 (en) 2021-05-18 2025-07-03 Onconic Therapeutics Inc. Parp inhibitor-resistant cancer therapeutic agent
WO2023089032A1 (en) * 2021-11-19 2023-05-25 Institut Curie Methods for the treatment of hrd cancer and brca-associated cancer
WO2023201338A1 (en) 2022-04-15 2023-10-19 Ideaya Biosciences, Inc. Combination therapy comprising a mat2a inhibitor and a parp inhibitor
EP4532493A1 (en) 2022-06-01 2025-04-09 Ideaya Biosciences, Inc. Thiadiazolyl derivatives as dna polymerase theta inhibitors and uses thereof
WO2024194402A1 (en) * 2023-03-21 2024-09-26 Institut Curie Farnesyl transferase inhibitor for use in methods for the treatment of hrd cancer
EP4683630A1 (en) * 2023-03-21 2026-01-28 Institut Curie Vps4b inhibitor for use in methods for the treatment of hrd cancer
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025183523A1 (ko) * 2024-02-29 2025-09-04 아주대학교 산학협력단 Parp 억제제 감수성 증가 방법
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5484951A (en) 1990-10-19 1996-01-16 Octamer, Incorporated 5-iodo-6-amino-6-nitroso-1,2-benzopyrones useful as cytostatic and antiviral agents
US5098861A (en) 1991-01-08 1992-03-24 Unitrode Corporation Method of processing a semiconductor substrate including silicide bonding
US5464871A (en) 1993-05-12 1995-11-07 Octamer, Inc. Aromatic nitro and nitroso compounds and their metabolites useful as anti-viral and anti-tumor agents
EP0600831A1 (de) 1992-11-27 1994-06-08 Ciba-Geigy Ag Phthalazinonderivate
GB9404485D0 (en) * 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
WO1999008680A1 (en) * 1997-08-15 1999-02-25 The Johns Hopkins University Method of using selective parp inhibitors to prevent or treat neurotoxicity
EP1140936B1 (en) * 1999-01-11 2004-03-17 Agouron Pharmaceuticals, Inc. Tricyclic inhibitors of poly(adp-ribose) polymerases
US6635677B2 (en) 1999-08-13 2003-10-21 Case Western Reserve University Methoxyamine combinations in the treatment of cancer
ECSP003637A (es) * 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas
DE10022925A1 (de) 2000-05-11 2001-11-15 Basf Ag Substituierte Indole als PARP-Inhibitoren
HRP20030081A2 (en) * 2000-08-08 2005-02-28 Sanofi-Aventis Benzimidazole derivatives, preparation and therapeutic use thereof
HU228960B1 (hu) 2000-10-30 2013-07-29 Kudos Pharm Ltd Ftalazinon-származékok
WO2002090334A1 (en) 2001-05-08 2002-11-14 Kudos Pharmaceuticals Limited Isoquinolinone derivatives as parp inhibitors
US7072771B2 (en) * 2001-06-07 2006-07-04 University Of Kentucky Research Foundation Selective PARP-1 targeting for designing chemo/radio sensitizing agents
US20030073692A1 (en) 2001-08-07 2003-04-17 Pharmacia & Upjohn S.P.A. Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
AUPS019702A0 (en) 2002-01-29 2002-02-21 Fujisawa Pharmaceutical Co., Ltd. Condensed heterocyclic compounds
US20030229004A1 (en) 2002-03-20 2003-12-11 Pangene Corporation Modulation of tumor cells using BER inhibitors in combination with a sensitizing agent and DSBR inhibitors
DE60335359D1 (de) 2002-04-30 2011-01-27 Kudos Pharm Ltd Phthalazinonderivate
AU2003253906A1 (en) 2002-07-19 2004-02-09 Osteotech, Inc. Chisels and procedure for insertion of spinal implant in a spinal disc space
PL1633724T3 (pl) * 2003-03-12 2011-10-31 Kudos Pharm Ltd Pochodne ftalazynonu
US7176188B2 (en) 2003-05-07 2007-02-13 UniversitéLaval Method of lethally sensitizing human and animal cells
GB0317466D0 (en) * 2003-07-25 2003-08-27 Univ Sheffield Use
MXPA06000993A (es) * 2003-07-25 2006-08-31 Cancer Rec Tech Ltd Inhbidores triciclicos de parp.
SG150548A1 (en) 2003-12-01 2009-03-30 Kudos Pharm Ltd Dna damage repair inhibitors for treatment of cancer

Also Published As

Publication number Publication date
DK1649017T3 (da) 2011-10-17
US20220062286A1 (en) 2022-03-03
EP1649017B1 (en) 2011-07-13
GB2419882B (en) 2008-04-09
ES2367433T5 (es) 2014-11-03
JP5848728B2 (ja) 2016-01-27
PT1649017E (pt) 2011-09-30
EP1649017B2 (en) 2014-08-27
CN1856572B (zh) 2013-11-06
NZ545307A (en) 2009-08-28
EP1649017A1 (en) 2006-04-26
BRPI0412909A (pt) 2006-09-26
CN1856313A (zh) 2006-11-01
JP5547164B2 (ja) 2014-07-09
CN1856313B (zh) 2011-01-12
AU2004261779A1 (en) 2005-02-10
CA2533423A1 (en) 2005-02-10
NO338398B1 (no) 2016-08-15
US8859562B2 (en) 2014-10-14
JP5519097B2 (ja) 2014-06-11
PL1649017T5 (pl) 2015-02-27
AU2004261779B2 (en) 2008-07-24
US20150005327A1 (en) 2015-01-01
US20070179160A1 (en) 2007-08-02
ATE516353T1 (de) 2011-07-15
JP2012102099A (ja) 2012-05-31
HK1094006A1 (en) 2007-03-16
CA2533423C (en) 2014-07-22
CN102935230A (zh) 2013-02-20
DK1649017T4 (da) 2014-12-01
US20200237762A1 (en) 2020-07-30
KR20060052877A (ko) 2006-05-19
NO20060906L (no) 2006-04-25
BRPI0412909B1 (pt) 2022-04-12
JP2014001210A (ja) 2014-01-09
ZA200601386B (en) 2007-04-25
KR101136702B1 (ko) 2012-04-20
CN1856572A (zh) 2006-11-01
ES2367433T3 (es) 2011-11-03
WO2005012524A1 (en) 2005-02-10
GB2419882A (en) 2006-05-10
CN102935230B (zh) 2016-08-10
JP2006528618A (ja) 2006-12-21
GB0603874D0 (en) 2006-04-05
PL1649017T3 (pl) 2011-12-30
HK1182016A1 (zh) 2013-11-22
US20180000822A1 (en) 2018-01-04

Similar Documents

Publication Publication Date Title
GB2419882B (en) Use of rnai inhibiting parp activity for the manufacture of a medicament for the treatment of cancer
WO2009045356A8 (en) Microrna compositions in the treatment of vegf-mediated disorders
WO2007022506A3 (en) Methods and compositions for treating neurological disease
AU2007257423A8 (en) Purine analogs
EP4413994A3 (en) Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
TW200637522A (en) Skin treatment articles and methods
TW200610756A (en) Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
IL249715B (en) N-butyl-deoxynojirimycin for use as a drug for the treatment of Pompe disease in combination with an enzyme replacement therapy agent
ZA200809250B (en) Tetrahydropyrrolopyrimidinediones and their use as human neutrophil elastase inhibitors
TNSN08140A1 (enExample)
SG170819A1 (en) Methods for the production of functional protein from dna having a nonsense mutation and the treatment of disorders associated therewith
MX341838B (es) Producción de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos.
WO2010083207A3 (en) Protein kinase c inhibitors and uses thereof
MX2010001993A (es) Metodos y composiciones para diagnosticar una enfermedad.
SG161286A1 (en) Methods for treating and preventing fibrosis by il-21 / il-21r antagonists
EP2069377A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF SKIN DISEASES AND SKIN FUNCTIONAL DISORDERS
MX349364B (es) Variante de alfa-1 antitripsina novedosa, método de preparación de la misma, y uso de la misma.
UA96926C2 (ru) Применение sdf-1 для лечения и/или профилактики неврологических заболеваний
IL194353A0 (en) Lysobactin amides
UA86399C2 (ru) Применение 2,5 дигидроксибензолсульфоновой кислоты для изготовления лекарства, которые применяют для лечения болезней, зависимых от ангиогенеза
NO20070780L (no) Celloverflateprotein.
TW200716153A (en) Mitotic kinesin inhibitors and methods of use thereof
DE502005005652D1 (de) Heterocyclyl-substituierte nonadepsipeptide
IL183926A0 (en) PHARMACEUTICAL COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH NF-kB ACTIVITY
GB0423126D0 (en) Protein

Legal Events

Date Code Title Description
COOA Change in applicant's name or ownership of the application

Owner name: UNIVERSITY OF SHEFFIELD, THE

Free format text: FORMER APPLICANT(S): UNIVERSITY OF SHEFFIELD, THE;UNIVERSITY OF NEWCASTLE UPON, THE TYNE

AT Applications terminated before publication under section 16(1)